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Abstract  49 
 50 
Background 51 
HE4 has emerged as a promising biomarker in gynaecological oncology. The purpose 52 
of this study was to evaluate serum HE4 as a biomarker for high-risk phenotypes in a 53 
population-based endometrial cancer cohort.  54 
 55 
Methods 56 
Peri-operative serum HE4 and CA125 were measured in 373 patients identified from 57 
the prospective Australian National Endometrial Cancer Study (ANECS). HE4 and 58 
CA125 were quantified on the Architect instrument in a clinically accredited 59 
laboratory. Receiver operator curves (ROC), Spearman rank correlation coefficient, 60 
chi-squared and Mann Whitney tests were used for statistical analysis. Survival 61 
analysis was performed using Kaplan-Meier and Cox multivariate regression analysis.  62 
 63 
 64 
Results 65 
Median CA125 and HE4 levels were higher in stage III and IV tumours (p<0·001) 66 
and in tumours with outer-half myometrial invasion (p<0·001). ROC analysis 67 
demonstrated that HE4 (Area under the curve (AUC)=0·76) was a better predictor of 68 
outer-half myometrial invasion than CA125 (AUC=0·65), particularly in patients with 69 
low-grade endometrioid tumours (AUC 0·77 vs 0·64 for CA125). Cox multivariate 70 
analysis demonstrated that elevated HE4 was an independent predictor of recurrence-71 
free survival (HR = 2·40, 95% CI 1·19-4·83, p = 0·014) after adjusting for stage and 72 
grade of disease, particularly in the endometrioid subtype (HR = 2·86, 95% CI 1·25-73 
6·51, p = 0·012).  74 
 75 
 4 
Conclusion 76 
These findings demonstrate the utility of serum HE4 as a prognostic biomarker in 77 
endometrial cancer in a large, population-based study. In particular they highlight the 78 
utility of HE4 for pre-operative risk stratification to identify high-risk patients within 79 
low-grade endometrioid endometrial cancer patients who might benefit from 80 
lymphadenectomy. 81 
  82 
 5 
Introduction 83 
Uterine cancer is the most common gynaecological cancer, and the fourth most 84 
common cancer overall among women in Western countries, with more than 280,000 85 
cases occurring annually worldwide [1]. The age-standardised incidence of uterine 86 
cancer is rising throughout the developed world [1] and this trend is expected to 87 
continue mainly due to the increasing prevalence of obesity. Approximately 90% of 88 
uterine cancers arise from the endometrium and are classified as endometrial 89 
adenocarcinomas (EAC). Eighty percent of EAC patients present with early stage, 90 
low-grade endometrioid endometrial carcinoma, commonly referred to as type 1 EAC. 91 
Approximately 20% of patients are diagnosed with high-risk histological subtypes 92 
(serous, clear cell or high-grade endometrioid), commonly referred to as type II EAC. 93 
 94 
The vast majority of endometrial cancer patients require surgery (total hysterectomy, 95 
bilateral salpingo-oopherectomy). Although lymph node status is included in the 96 
current FIGO staging of EAC, there is a lack of consensus regarding the role of 97 
routine lymphadenectomy, particularly as it increases surgical complexity and has not 98 
been shown to have a therapeutic benefit [2, 3].  99 
 100 
Uterine pathological factors such as tumour grade and depth of myometrial invasion 101 
correlate with a patient’s probability of node metastasis to a large extent. Patients with 102 
low-grade tumours and no or only inner-half myometrial invasion are at negligible 103 
risk of lymph node metastases. As a consequence, many groups advocate an approach 104 
where patients at negligible risk of lymph node metastases are spared 105 
lymphadenectomy [4]. However identification of these patients before surgery 106 
remains challenging, and thus the decision to perform a lymphadenectomy is often 107 
based on intra-operative frozen section to assess histological grade and depth of 108 
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myometrial invasion.  Frozen section is not available in all centres both nationally and 109 
internationally, and conflicting reports regarding its reliability in surgical staging of 110 
endometrial cancer [5-8] suggest significant inter- and intra-observer variability. 111 
 112 
The availability of a highly standardized and reliable pre-operative biomarker would 113 
enhance risk assessment greatly. Serum markers could predict the absence of high-114 
risk uterine features even prior to surgery to identify which patients should be spared 115 
lymphadenectomy. However, despite active research in this area, no such biomarker is 116 
currently accepted for routine use in clinical practice. In addition although the 117 
majority of EAC’s have an inherently good prognosis, recurrence occurs in 13-17% of 118 
women, mostly within 3 years of primary treatment [9, 10]. Prognostic biomarkers 119 
that could stratify patients by recurrence risk would allow for more personalized, and 120 
thus more cost effective post-operative care. 121 
 122 
Human epididymis protein 4 (HE4), initially identified as one of four cDNAs highly 123 
expressed in the human epididymis [11] is a secreted protein that is overexpressed in 124 
patients with serous and endometrioid epithelial ovarian[12, 13] and uterine cancers 125 
[14-16].  Although the true functional role of HE4 in carcinogenesis has yet to be 126 
fully elucidated, it is generally agreed that HE4 plays a role in natural immunity[17]. 127 
Multiple studies have reported its utility as an ovarian cancer biomarker (reviewed in 128 
[18]) and in 2009, the United States Food and Drug Agency (FDA) approved HE4 as 129 
an aid in monitoring recurrence or progressive disease in patients with epithelial 130 
ovarian cancer. 131 
 132 
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There is accumulating evidence that HE4 may also prove to be a useful marker for 133 
endometrial cancer. HE4 has been shown to be elevated in patients with EAC 134 
compared to healthy controls [14-16], and single institutional analyses of relatively 135 
small retrospective cohorts suggest that increased HE4 levels may be associated with 136 
myometrial invasion [15, 19, 20] and poor prognosis [15, 16, 21]. The aim of the 137 
present analysis was to assess peri-operative serum HE4 levels as a biomarker of 138 
disease severity in a large-population-based EAC cohort. 139 
 140 
 141 
 142 
Methods 143 
 144 
Patients 145 
The Australian National Endometrial Cancer study (ANECS) was a large, Australia-146 
wide, population-based, case-control study of endometrial cancer conducted between 147 
2005 and 2007 [22]. Women aged 18-79 years, diagnosed with endometrial cancer 148 
during this period were recruited through treatment clinics and state-based cancer 149 
registries, the final sample comprised 1458 eligible women, however a significant 150 
proportion of these patients were recruited after they had had definitive surgery. The 151 
study was approved by the Human Research Ethics Committees at the Queensland 152 
Institute of Medical Research and all participating hospitals and cancer registries. 153 
Patients were included in this serum study if they had a peri-operative serum sample 154 
and complete pathological data: 343 patients (90%) had pre-operative samples taken, 155 
and the remaining 40 patients (10%) had blood taken on day 1 or 2 post-surgery. 156 
Median follow-up time for this cohort was 37 months. Ten patients had a follow-up 157 
less than 6 months in this study and 19 patients has a follow-up between 6 and 12 158 
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months.  Standard treatment was total hysterectomy (laparoscopic or abdominal) and 159 
bilateral salpingo-oophorectomy. The proportion of patients who had formal surgical 160 
staging and adjuvant treatment is outlined in table 1. 161 
 162 
 163 
Quantification of HE4 and CA-125 in human serum 164 
 165 
Bloods were taken at local sites and transported at room temperature prior to 166 
processing. The median time from blood drawing to processing for samples included 167 
in this study was 3 days (range 0 -13 days).  Serum was stored at −80°C until analysis. 168 
Specimens were analyzed in a clinically accredited laboratory by means of 169 
chemiluminescent microparticle immunoassays specific for HE4 (ARCHITECT HE4 170 
assay; Abbott Diagnostics, Lane Cove, NSW, Australia) or CA125 (ARCHITECT 171 
CA125 II assay; Abbott Diagnostics, Lane Cove, NSW, Australia). The dynamic 172 
range of HE4 detection goes from 20 to 1500 pM with an automated 1:10 dilution 173 
protocol that extends the linear range up to 15,000 pM. The intra-assay and total 174 
imprecision (CV%) of the CMIA HE4 assay has previously been demonstrated to 175 
range from 2·11 to 2·93 and from 3·13 to 3·70 depending on the concentrations of the 176 
positive controls used [23].  The CA125 assay is linear up to 1000 U/mL and has a 177 
normality threshold at 35 U/mL.  178 
 179 
Statistics 180 
HE4 and CA125 protein levels were compared across groups using the Mann Whitney 181 
test. The 2 or Fisher’s exact test were used for categorical data. Spearman's rank 182 
correlation coefficient was used to estimate the relationship between quantitative HE4 183 
data and age and body-mass index (BMI, kg/m
2
). Receiver operator curves (ROC) 184 
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were used to compare the ability of HE4 and CA125 to identify patients with outer-185 
half myometrial invasion. Recurrence-free survival (RFS) was calculated from date of 186 
surgery to date of histological confirmation of recurrence or the date a woman was 187 
last known to be alive and recurrence-free. Overall survival (OS) was calculated from 188 
date of surgery to date of death or the date a woman was last known to be alive. 189 
Kaplan-Meier analysis and the log rank test were used to illustrate differences 190 
between OS and RFS according to HE4 and CA125 expression. Cox proportional 191 
hazards models were used to estimate the relationship between HE4 and CA125 and 192 
survival, controlling for other clinical variables. Variables that were significant in 193 
univariate analysis (grade, stage, histological subtype, lymphovascular space invasion 194 
(LVSI) and adjuvant treatment) were assessed for inclusion in the multivariate 195 
models. Age was not included as it was not a significant predictor of OS or RFS in 196 
univariate analysis. All calculations were performed using IBM SPSS Statistics 197 
version 20·0·0 (IBM Corporation, Armonk, New York, USA). A P value < 0·05 was 198 
considered statistically significant. Statistical comparison of ROC curves (StAR) was 199 
used to compare AUC values for HE4 and CA125 as previously described[24]. 200 
 201 
Results 202 
 203 
A total of 373 peri-operative serum samples were successfully analyzed for HE4 and 204 
CA125. The distribution of HE4 and CA125 levels did not differ between samples 205 
taken pre- or post-operatively (Supplemental Figure 1, Supplemental table 1).  Table 1 206 
shows the characteristics of women included in the HE4 sub-study (n=373) compared 207 
to the rest of the ANECS cohort (n=1085), and demonstrates that, with the exception 208 
of LVSI and BMI, the cohort used for the HE4 substudy was a representative sample 209 
of the ANECS cohort.  Patients in the HE4 substudy sample had a mean age (SEM) of 210 
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61·2 (0·52) years, and the mean BMI (SEM) was 32·5 kg/m
2 
(0·44). During a median 211 
follow-up period of 37 months (range 1 to 63 months), 43 patients developed a 212 
recurrence and 20 of these patients died (16 confirmed cancer-specific deaths). 213 
 214 
The association between serum HE4 and CA125 levels and clinico-pathological 215 
characteristics is shown in Table 2. The median serum HE4 concentration of all 216 
patients was 75·5 pmol/l (range 21–1163 pmol/l) and the median CA125 was 15·4 217 
U/ml (range 1-568 U/ml).  CA125 was greater than 35 U/ml, the established clinical 218 
threshold used for the assay, in 50 (13%) patients. HE4 and CA125 demonstrated a 219 
moderate correlation (Spearman's rank r=0·349; p<0·001).  Serum HE4 levels were 220 
associated with increasing age (r=0·342, p<0·001) and BMI (r=0·147, p=0·005)· 221 
CA125 was not associated with age or BMI. Median HE4 levels were significantly 222 
higher in patients with advanced stage disease, outer-half myometrial invasion, 223 
patients who developed recurrent disease, and a history of diabetes or hypertension, 224 
but were not associated with cell type (endometrioid vs other), or LVSI (Table 2). 225 
Median CA125 levels were significantly higher in patients with advanced stage 226 
disease and outer-half myometrial invasion and those who subsequently developed 227 
recurrent disease (Table 2). 228 
 229 
Area-under-the-curve (AUC) analysis of HE4 vs CA125 in regards to the prediction 230 
of outer-half myometrial invasion in the evaluated cohort (n=373) revealed a 231 
significantly higher AUC for HE4 compared to CA125 (p=0.007) (Figure 1A). The 232 
superiority of HE4 over CA125 was strengthened when the analysis was limited to 233 
endometrioid endometrial cancer patients (n =316), and remained so even for grade I 234 
and II endometrioid endometrial cancer (n= 280) tumours (Figures 1B and C). Due to 235 
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the small number of non-endometrioid tumours we were unable to assess the ability of 236 
HE4 and CA125 to predict outer-half myometrial invasion in this subset. A logistic 237 
regression model combining HE4 and CA125 (AUC for model 0·76, 95% CI 0·70-238 
0·82) did not improve the predictive value of HE4 alone (AUC 0·76 (95% CI 0·70-239 
0·81)) for assessing depth of myometrial invasion. The sensitivity and specificity of 240 
HE4 to predict myometrial invasion was assessed using a threshold of 70 pmol/L as 241 
previously published [19]. This value was close to the median level (75·5 pmol/L) in 242 
our study population (Table 3). A HE4 level of 70 pmol/L was associated with a 243 
sensitivity of 83%, a specificity of 53% and a negative predictive value of 92% when 244 
assessing depth of myometrial invasion in the evaluated cohort (n=373). These figures 245 
remained very similar when the analysis was restricted to endometrioid histology 246 
alone (n=316), low-grade endometrioid histology (n=280) and early stage 247 
endometrioid histology (n=295). Application of the 75
th
 percentile, which was used 248 
for survival analysis (see below) demonstrated that HE4 had a sensitivity of 53%, a 249 
specificity of 83% and a negative predictive value of 86% when assessing myometrial 250 
invasion in the evaluated cohort (n=373), suggesting that a lower threshold may be 251 
more effective in this setting.  252 
 253 
Kaplan-Meier analysis demonstrated that increased HE4 levels were associated with 254 
impaired RFS and OS; however, curves for the first 3 quartiles of HE4 overlapped 255 
and only patients with HE4 levels between the 75
th
 to 100
th
 percentiles differed 256 
significantly. Therefore data were dichotomized based on the 75
th
 percentile (HE4 ≥ 257 
113 pmol/L), which demonstrated that increased HE4 at this level was associated with 258 
a significantly reduced RFS and OS in the evaluated cohort (n=373) (both p<0·001 259 
compared to women below the 75
th
 percentile, Figure 2A and B). A similar pattern 260 
was seen in the subset of women with endometrioid histology (n=316) (Figure 2C and 261 
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D). Given the similarity between the results for RFS and OS, further analyses focused 262 
on RFS. 263 
 264 
Univariate analysis showed that stage, grade, histological subtype, LVSI, CA125 and 265 
HE4 were all significantly associated with RFS; however these variables were all 266 
highly correlated. Forward stepwise regression suggested that in multivariable models 267 
the only independent clinical predictors of RFS were stage and grade, thus further 268 
models were adjusted for these characteristics. After adjustment for stage and grade, 269 
CA125 was not significantly associated with RFS (HR = 1·94, 95% CI 0·88-4·25, p = 270 
0·099). The association between RFS and HE4, however, remained strong and 271 
statistically significant even after adjustment (HR = 2·40, 95% CI 1·19-4·38, p = 272 
0·014) (Table 4). Similar results were seen when the cohort was restricted to 273 
endometrioid endometrial cancer (HR = 2·86, 95% CI 1·25-6·51, p = 0·012) and to 274 
low-grade (G1/2) endometrioid endometrial cancer (HR=2·99, 95% CI 1·16-7·71, p = 275 
0·024).  276 
 277 
Discussion 278 
 279 
Additional biomarkers are urgently required for endometrial cancer to allow pre-280 
operative stratification of patients based on their likely risk of recurrence, to inform 281 
the extent of surgery performed and planning of appropriate personalized therapeutic 282 
regimens. A pre-operative serum-based assay would be the least invasive and most 283 
cost-effective approach. Currently no marker has received universal approval. 284 
Although some units use preoperative serum CA125 its sensitivity and specificity is 285 
low and its main utility appears to predict extra-uterine disease, which is uncommon 286 
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in EAC [25]. Several small single institutional studies have suggested HE4 may be of 287 
value for EAC risk stratification [15, 19-21]. In the present population-based study of 288 
373 cases, we used a clinically accredited and highly standardized test to provide the 289 
first definitive description of HE4 as a prognostic biomarker in EAC. The findings 290 
demonstrate that the HE4 serum assay should be considered for future pre-operative 291 
triage of EAC cancer patients. 292 
 293 
The strengths of this study include the fact that it was a population-based cohort. HE4 294 
and CA-125 analysis were performed in a clinically accredited laboratory and the 295 
median HE4 levels were similar to previous publications [15, 19-21].  Weaknesses of 296 
the study include the fact that there was no central pathology review and it is thus 297 
possible that minor components of high grade or aggressive subtypes could be 298 
identified by future review of individual low-grade endometrioid tumours. However 299 
this is unlikely to bias our results given that associations for HE4 with myometrial 300 
invasion are strongest for endometrioid tumours irrespective of grade. As a 301 
consequence of the national recruitment protocol, blood was not processed 302 
immediately after draw, however HE4 has been shown to remain stable across 303 
multiple freeze-thaw cycles and when stored at room temperature for over 72 hours 304 
[18]. Finally, although renal failure is a well-recognized cause of elevated HE4 in 305 
benign disease [26, 27], we were unable to control for this as baseline renal function 306 
was not available for patients in this study. 307 
 308 
An association between a serum marker and an aggressive EAC phenotype may have 309 
important clinical implications, as pre-operative serum HE4 testing may offer 310 
preliminary pre-operative risk stratification. Lymphadenectomy as part of the staging 311 
procedure remains the most controversial issue in the management of EAC. 312 
Nevertheless, the current lack of an appropriate pre-operative test to effectively 313 
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estimate the likely extent of disease precludes the surgeon from identifying and 314 
counseling those patients who could potentially benefit from lymphadenectomy. MRI 315 
has been used to triage patients pre-operatively, however its sensitivity and cost 316 
effectiveness have been questioned. Reports on the accuracy of MRI in predicting 317 
depth of myometrial invasion vary widely from 46·6% to 93% with negative 318 
predictive values of 71– 92·3%[28].  319 
 320 
Herein we present 70 pmol/l as a threshold for HE4 to predict outer-half myometrial 321 
invasion (Table 3). Moore et al previously demonstrated that an HE4 threshold of 70 322 
pmol/l had a sensitivity of 82% with a NPV of 82% in distinguishing stage 1A from 323 
all other endometrioid endometrial cancer [19]. We present similar figures for 324 
sensitivity but an improved NPV (Table 3). 325 
 326 
Taken together, these data suggest that HE4 can be used to effectively triage patients 327 
pre-operatively as a patient with a low grade tumour on curette and a low HE4 (< 70 328 
pmol/l) is extremely unlikely to be diagnosed with outer-half myometrial invasion, 329 
bears a low risk of lymph node metastases and could potentially avoid 330 
lymphadenectomy. By contrast, patients with low-grade tumours on curette but a high 331 
preoperative HE4 may indicate a high-risk EAC phenotype and may benefit from a 332 
lymphadenectomy to ascertain the extent of the disease and inform decisions on 333 
adjuvant therapy. 334 
 335 
Yet another future use to be considered for HE4 serum assays may be for post-336 
operative follow-up of patients with endometrial cancer.  A proportion of patients 337 
with “low-risk” early stage disease will recur within the first 3 years, and to date no 338 
single approach has been shown to be effective for monitoring of patients for possible 339 
recurrence. Our finding that RFS at 3 years for patients with peri-operative HE4 > 75
th
 340 
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percentile was 78% versus 93% in patients with a HE4 < 75
th
 percentile, suggests that 341 
the 25% of patients with such increased peri-operative HE4 may be suitable for more 342 
intense follow-up.  Future studies of the natural history of HE4 in recurrent 343 
endometrial cancer will, however, be required before it can be used in routine follow-344 
up. 345 
 346 
In summary, these data from a large, population-based cohort confirm previous 347 
smaller reports that elevated HE4 is associated with an aggressive EAC phenotype, 348 
even within the subset of low-grade endometrioid endometrial cancer. HE4 is an 349 
independent poor prognostic marker and is superior to CA125 as a predictor of outer-350 
half myometrial involvement. The NPV and sensitivity values presented here are 351 
comparable to those previously published for MRI and suggest that HE4 may be a 352 
more cost-effective approach in identifying patients who are low risk to avoid 353 
unnecessary lymphadenectomy.  354 
 355 
 356 
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